Products for Research Use Only

GP (33-41) (TFA)

CAT: 0804-HY-P0323A-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P0323A-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
GP (33-41) TFA, a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus. GP (33-41) TFA can upregulate H-2Db molecules at the RMA-S (Db Kb) cell surface with a SC50 of 344 nM[1].
UNSPSC
12352209
Target
Arenavirus
Type
Peptides
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/gp-33-41-tfa.html
Purity
99.62
Solubility
DMSO : ≥ 50 mg/mL|H2O : 1.82 mg/mL (ultrasonic; adjust pH to 4 with HCl)
Smiles
O=C(N[C@@H](CC(N)=O)C(N[C@H](C(N[C@@H](C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CS)C(O)=O)=O)=O)=O)CC1=CC=CC=C1)=O)[C@@H](NC([C@H](C(C)C)NC([C@H](C)NC([C@@H](N)CCCCN)=O)=O)=O)CC(C=C2)=CC=C2O.OC(C(F)(F)F)=O
Molecular Formula
C48H70F3N11O15S
Molecular Weight
1130.19
References & Citations
[1]Gairin JE, et al. Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes. J Virol. 1995 Apr;69 (4) :2297-305.|[2]Boulter JM, et al. Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. Eur J Immunol. 2007 Mar;37 (3) :798-806.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
Scientific Category
Peptides
Clinical Information
No Development Reported

Popular Products